



One Test for a Clean Bill of Gynecological Health

Bella One PAP™

genetic molecular cervical test

Boost effectiveness of patient testing

Awareness about the link between HPV and cervical cancer has grown exponentially – leading to earlier detection and prevention. The CDC estimates that up to 93 percent of cervical cancers can be prevented. And yet, 33 percent of the 12,000 women who are diagnosed annually will die.

The Bella One PAP is the first FDA-approved test to screen not only for 14 high-risk strains of HPV, but also for other sexually transmitted infections that pose a threat to women's health. Often symptomless, these gynecological conditions can cause irreversible damage to women's reproductive system and overall health – making it all the more important for sexually active women to be tested regularly.

Provide your patients with a streamlined screening experience by administering one simple test that encompasses a molecular PAP smear while accounting for a range of other harmful conditions.

Early screening is crucial to survival. As with cervical cancer, if we can identify the virus DNA and RNA responsible for precancerous and cancerous cervical lesions, we can change the course of the disease. Survival rates can jump from near hopelessness to a happy ending with little interruption. Patients need to be tested annually and or as clinically indicated.

Why Bella One?

The Bella One PAP screens for presence of Human Papilloma Virus DNA and RNA as well as precancerous cells to determine whether a woman is at high-risk for developing cervical precancerous or cancerous conditions. – in addition Bella One Pap is design to test for a host of other infectious gynecological conditions.

One Simple Test

Unlike regular PAP smears, Bella One is the comprehensive test that provides an overall assessment of gynecological health.

Early Detection

The Bella One PAP detects cell abnormalities and high-risk strains of HPV that increase the odds of developing cervical cancer – enabling more targeted monitoring in at-risk patients.

Prevent Permanent Damage

Because many women present few symptoms – or none at all – certain STI's like gonorrhea, trichomonas, and chlamydia can go unnoticed for too long, creating complications that could last a lifetime.

value for your practice


educating patients

We recommend that women be given the Bella One PAP in lieu of the traditional pap. We strive to be a partner with you in this effort and will provide you all the necessary tools to create value for your patients and your practice, such as:

- A patient education flyer *that explains the importance of the screen and what to expect via results.*
- A consent form *for the patient to sign so refusals can be placed in their file.*
- A negative letter *if patients results are negative PCG Molecular will send your patient a letter in the mail on your behalf within 5 business days.*

What is the procedure like?

The patient experience is similar and or less invasive than the traditional pap smear collection. The collection tool is slightly different, resembling more of a brush that reaches both the vagina and the uterine cervix and still gently lifts cells as it did before. To self collect this cervical specimen, instructions are provided for the patient and or medical provider that explains step by step the collection procedure.



helping you communicate lab results

for negative results

PCG Molecular will send your patients a letter in the mail on your behalf within 5 business days if patient results are negative.

for “watch” or high risk results

Being placed on a watch is no reason for patients to panic. It doesn't mean they have cervical cancer or that they will ever get them. All it means is that we need to watch their cases more closely. We will send you a report and give you a sample letter to send to your patients that communicates the results and what next steps to follow.

for positive results

You will receive a detailed report for those patients that test positive for precancerous or cancerous cells, or sexually transmitted infections. These patients may require additional tests, along with a personal call. We can advise you of next steps and referrals if you need them.

PCG Molecular is a preventive care diagnostic company re-engineering the way we approach health care. The pioneering company is dedicated to the development of molecular genetic screens that detect early signs of DNA and cellular damage.